Evidenzbasierte Therapie der Sepsis - Antiinfektiöse Strategien mit supportiven und adjunktiven Maßnahmen kombinieren

Zusammenfassung

Die Therapie der schweren Sepsis und des septischen Schocks besteht aus der Sanierung des infektiösen Fokus, supportiven Maßnahmen sowie einer adjunktiven Therapie. Adjunktive Therapiemaßnahmen können jedoch nur dann sinnvoll eingesetzt werden, nachdem die Fokussanierung und die supportiven Behandlungen eingeleitet worden sind. Für viele Teilfragen in der Behandlung existieren lediglich Behandlungsoptionen mit niedrigem Empfehlungsgrad. Doch gab es gerade in den letzten Jahren auch große Studien mit hohem Evidenzgrad, aus denen sich eindeutigere Empfehlungen ableiten lassen. Dies sind für die supportiven Behandlungen die initiale Kreislaufstabilisierung nach den Kriterien der „early goal directed therapy”, lungenprotektive Beatmungsverfahren sowie Thrombose- und Ulkusprophylaxe.

Bei den adjunktiven Behandlungen gibt es entsprechende Empfehlungen für niedrig dosiertes Hydrokortison und rekombinantes humanes aktiviertes Protein C.

Summary

The treatment of severe sepsis and septic shock consists of the control of the infectious focus as well as supportive and adjunctive therapies. Adjunctive treatment strategies can only be applied if focus control and sufficient supportive measures are initiated. Only treatment options with a low recommendation grade still exist for many subquestions. However, several large studies with a good level of evidence have been published especially during the last couple of years allowing the expression of clear recommendations. This includes the initial cardiovascular resuscitation according to the Early Goal Directed Therapy, lung protective ventilation as well as stress ulcer and deep vein thrombosis prophylaxis for the supportive therapies. For the adjunctive therapy, application of low-dose hydrocortisone and/or recombinant humane activated protein C is recommended.

sepsis - focus control - early goal directed therapy - hydrocortisone - protein C

Literatur

• 1 Abraham E, Reinhart K, Opal S. et al. . Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.  JAMA. 2003;  290 238-247
• 2 Annane D, Sebille V, Charpentier C. et al. . Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
• 3 Annane D, Sebille V, Troche G. et al. . A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.  JAMA. 2000;  283 1038-1045
• 4 Bernard GR, Vincent JL, Laterre PF. et al. . Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 5 Cochrane Injuries Group Albumin Reviewers. . Human albumin administration in critically ill patients: systematic review of randomised controlled trials.  BMJ. 1998;  317 235-240
• 6 Dellinger RP, Carlet J, Masur H. et al. . Surviving Sepsis Campaign for management of severe sepsis and septic shock.  Intensive Care Med. 2004;  30 536-555
• 7 Ely EW, Angus DC, Williams MD. et al. . Drotrecogin alfa (activated) treatment of older patients with severe sepsis.  Clin Infect Dis. 2003;  37 187-195
• 8 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis.  N Engl J Med. 2003;  348 138-150
• 9 International Sepsis Forum. . Guidelines for the management of severe sepsis and septic shock.  Intensive Care Med. 2001;  27 S1-S134
• 10 Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000.  N Engl J Med. 2003;  348 1546-1554
• 11 Moerer O, Schmid A, Hofmann M. et al. . Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use.  Intensive Care Med. 2002;  28 1440-1446
• 12 Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis.  Nat Med. 2003;  9 517-524
• 13 Rivers E, Nguyen B, Havstad S. et al. . Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med. 2001;  345 1368-1377
• 14 Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials.  BMJ. 1998;  316 961-964
• 15 The Acute Respiratory Distress Syndrome Network . Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.  N Engl J Med. 2000;  342 1301-1308
• 16 van den Berghe G, Wouters PJ, Bouillon R. et al. . Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control.  Crit Care Med. 2003;  31 359-366
• 17 van den Berghe G, Wouters P, Weekers F. et al. . Intensive insulin therapy in the critically ill patients.  N Engl J Med. 2001;  345 1359-1367
• 18 Vincent JL, Abraham E, Annane D. et al. . Reducing mortality in sepsis: new directions.  Crit Care. 2002;  6 S1-S18
• 19 Warren BL, Eid A, Singer P. et al. . Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878

1 acute physiology and chronic health evaluation

2 administration of drotrecogin alfa (activated) in early severe sepsis

Anschrift für die Verfasser